Analyzing Assertio (NASDAQ:ASRT) & Sandoz Group (OTCMKTS:SDZNY)

Assertio (NASDAQ:ASRT) and Sandoz Group (OTCMKTS:SDZNY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Volatility & Risk

Assertio has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Sandoz Group has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Assertio and Sandoz Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1	1	2	0	2.25
Sandoz Group	0	3	0	0	2.00

Assertio currently has a consensus price target of $2.38, indicating a potential upside of 175.97%. Given Assertio’s stronger consensus rating and higher possible upside, analysts clearly believe Assertio is more favorable than Sandoz Group.

Profitability

This table compares Assertio and Sandoz Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Assertio	-36.97%	-38.19%	-15.45%
Sandoz Group	N/A	N/A	N/A

Insider & Institutional Ownership

49.0% of Assertio shares are held by institutional investors. Comparatively, 0.1% of Sandoz Group shares are held by institutional investors. 4.0% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Assertio and Sandoz Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$124.96 million	0.66	-$21.58 million	($0.45)	-1.91
Sandoz Group	$10.36 billion	2.58	$1.00 million	N/A	N/A

Sandoz Group has higher revenue and earnings than Assertio.

Summary

Sandoz Group beats Assertio on 7 of the 12 factors compared between the two stocks.

About Assertio

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.